July 13, 2022
ASCO 2022 Lymphoma In-Depth BookmarkGeorge Lundberg, MD
Presented by Cancer Therapy Advisor, this collection of stories covers new developments in lymphoma treatment that were presented at the 2022 annual meeting of the American Society of Clinical Oncology.
July 28, 2021
2021 ASCO Annual Meeting BookmarkGeorge Lundberg, MD
Researchers at the 2021 annual meeting of the American Society of Clinical Oncology (ASCO) reported substantial advances in treatment for advanced esophageal, castration-resistant prostate, and metastatic nasopharyngeal cancers.
January 7, 2019
ASCO and Friends of Cancer Research Applaud NCI’s Expansion of Clinical Trial Eligibility Criteria BookmarkEmma Shtivelman, PhD
“ASCO and Friends of Cancer Research (Friends) applaud the National Cancer Institute’s (NCI) recent revision of its clinical trial protocol template to broaden eligibility criteria for cancer clinical trials. The protocol template was expanded to help increase the opportunity for participation in NCI-funded clinical trials for patients with certain health-care conditions, as well as to provide an opportunity for patients younger than age 18 to participate in adult clinical trials in certain circumstances.”
Go to full article published by The ASCO Post on Dec 11, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
June 12, 2015
Melanoma at ASCO 2015: Immunotherapy Continues to Make HeadlinesEmma Shtivelman, PhD
The biggest news in melanoma treatment from the 2015 American Society of Clinical Oncology (ASCO) annual meeting was undoubtedly the report from a large, phase III, randomized clinical trial that compared a combination of two ‘checkpoint inhibitor’ drugs—nivolumab (Opdivo) and ipilimumab (Yervoy)—with the same drugs given alone. In the CheckMate-067 trial, 945 previously untreated patients with unresectable stage III or IV melanoma were assigned… Read more »